Study_Mentioned
stringlengths 3
205
⌀ | Product_Mentioned
stringlengths 3
429
⌀ | Company_Mentioned
stringlengths 3
288
| Indication_Mentioned
stringlengths 2
111
| Non_Social
int64 1
1
| Tag
stringlengths 2
1.13k
⌀ | Adjusted_Date
stringlengths 11
16
| Conversation_Id
float64 422,000,000B
1,680,000,000B
| Clean_Tweet
stringlengths 1
298
⌀ | Profile_Bio
stringlengths 1
185
⌀ | Class
stringclasses 6
values | User_Type
stringclasses 17
values |
|---|---|---|---|---|---|---|---|---|---|---|---|
paradigm | panitumumab | amgen,takeda | gi | 1 | ['paradigm'] | 6/5/2022 17:48 | 1,530,000,000,000,000,000 | terrific commentary on #paradigm study led by at #asco22 plenary session inspiring example! | Medical Oncologist @IEOUfficiale, PhD student @unipv ???? Former Research Fellow @clevelandclinic ???? Big UC @sampdoria fan. Passionate about #GIcancer & #VTE | Individual | HCP |
improve | panitumumab | amgen,takeda | gi | 1 | ['#gi', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'crcsm', 'improve '] | 6/6/2022 10:52 | 1,530,000,000,000,000,000 | dr presents the study schema for his improve trial looking at intermittent vs continuous folfiri + pan for unresectable ras/braf wt metastatic #crcsm #gionc #asco22 | #FosterCare alum, #GIonc, #pallonc, and #survonc doc @ParkviewHealth.Uniting support and cancer care #supponc #hpm #hapc Tweets are own. | Individual | HCP |
TRIPLETE | panitumumab | Amgen,Takeda | other,gi | 1 | ['colorectal', 'triplet', 'triplete', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'crcsm', 'rectal'] | 6/6/2022 11:20 | 1,530,000,000,000,000,000 | mfolfoxiri plus pani (mfolfoxiri/pan) versus mfolfox6/pan as initial treatment of patients with unresectable ras and braf wild-type metastatic colorectal cancer (mcrc): results of the phase iii triplete trial by gono. talk by dr #asco22 #crcsm | Pt Adv, NCI Rectal Anal TF
Mom, lifelong learner
Wants to bring patient voice to research, clinical trials & more!
Check out @CRCTrialsChat
1st love: Virology | Individual | Advocacy / Charity |
paradigm | panitumumab | amgen,takeda | gi | 1 | ['paradigm'] | 6/5/2022 9:24 | 1,530,000,000,000,000,000 | if we are going to recommend treatment paradigms to our patients, we should be able to counsel them on what their quality of life and symptom burden will be like with those paradigms. pros should be in all trials. #asco22 cc | Heme/onc fellow. #lymsm & #mmsm patient-reported outcomes researcher. Founder of https://t.co/kN6qeGFEox, @inTrainingDoc & @inHouseMag. ?????? | Individual | HCP |
paradigm | panitumumab | amgen,takeda | gi | 1 | ['panitumumab', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)'] | 6/5/2022 13:10 | 1,530,000,000,000,000,000 | dr. yoshino lba1 #asco22: hr for death was 0.82 (p=0.031) for panitumumab in l-sided crc | Oncologist & Chief Medical Science Officer @ASCO #CancerLinQ. Classical/choral music fan ???? https://t.co/GxpBhxmsFj. RT or like may mean I agree; or not. Tweets=only moi | Individual | Professional |
paradigm | panitumumab | amgen,takeda | gi | 1 | ['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'paradigm'] | 6/5/2022 13:17 | 1,530,000,000,000,000,000 | #asco22 plenary session #1. paradigm trial. first prospective study to show os improvement in left-sided mcrc with egfri vs vegfi. unclear why pfs was not extended in 1l. | Hematology/Oncology fellow @EinsteinMed @MontefioreNYC via @slusom and @USJLiban. Interested in EBM & clinical reasoning. Views are my own. | Individual | HCP |
paradigm | panitumumab | amgen,takeda | gi | 1 | ['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'paradigm'] | 6/5/2022 13:18 | 1,530,000,000,000,000,000 | new 1l in ras wt mcrc based on os and pfs benefit in ph3rct paradigm #plenary #asco22 presented by dr yoshino | Regional Cancer Research Director @CleveClinicFl #Scientist #Immune #Oncology #Epigenetics #Cancer #Sensitisation #TIME #StayPositive. Tweets are mine. | Individual | HCP |
paradigm | panitumumab | amgen,takeda | gi | 1 | ['paradigm'] | 6/5/2022 13:23 | 1,530,000,000,000,000,000 | do not miss prof. cremolini discussing the paradigm trial in #asco22 plenary session! | null | Individual | HCP |
paradigm | panitumumab | amgen,takeda | gi | 1 | ['paradigm'] | 6/5/2022 13:23 | 1,530,000,000,000,000,000 | paradigm trial conclusions at the 2022 plenary. game changing? share your thoughts #asco22 | Narjust Duma, MD, (@NarjustDumaMD) #LCSM Oncologist from @DanaFarber, takes over our Twitter today to discuss #ASCO22. | Company / Organization | Media / News |
paradigm | panitumumab | amgen,takeda | gi | 1 | ['paradigm'] | 6/5/2022 13:26 | 1,530,000,000,000,000,000 | great discussion of regarding the results of the paradigm trial in #asco22 | Medical Oncologist & Internal Medicine. Clinical Epidemiologist & Pharmacologist.
I'm working, studying, learning, traveling, teaching, or just enjoying life! | Individual | HCP |
paradigm | panitumumab | amgen,takeda | gi | 1 | ['paradigm'] | 6/5/2022 13:30 | 1,530,000,000,000,000,000 | i can't express how i'm excited to see a powerful discussing the #paradigm trial at #asco22 her first note: when an analysis is exploratory, be cognizant it's hypothesis -generating. in the | Medical Oncologist | Individual | HCP |
paradigm | panitumumab | amgen,takeda | gi | 1 | ['panitumumab', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'paradigm'] | 6/5/2022 13:34 | 1,530,000,000,000,000,000 | location, location, location! left-sided mcrc benefit from first-line treatment with panitumumabe + mfolfox6 and saying goodbye to the 30m survival mark in mcrc! #asco2022 #paradigm | Maria Cecília Mathias - Medical Oncologist and GI Fellow @grupoOncoclínicas ?? Former Oncology Fellow @ ICESP | ?? Baiana ??????and proud of it! ???? | Individual | HCP |
paradigm | panitumumab | amgen,takeda | gi | 1 | ['paradigm', 'gi '] | 6/5/2022 13:38 | 1,530,000,000,000,000,000 | not gi onc, but who is surprised at pfs, os and rr data from paradigm trial - great discussion #ascoplenary #asco22 | Breast Onc/Genetics enthusiast @BillingsClinic Chief Fellow @UNM Chief Resident @Einsteinhealth Opinions mine She/Her #IMG #MedEd #MedicareForAll #Oncology | Individual | HCP |
paradigm | panitumumab | amgen,takeda | gi | 1 | ['paradigm'] | 6/5/2022 13:44 | 1,530,000,000,000,000,000 | paradigm trial
fantastic discussion by | Medical Oncology Resident, European Institute of Oncology (@IEOufficiale), Milan | Individual | HCP |
paradigm | panitumumab | amgen,takeda | gi | 1 | ['panitumumab', 'crcsm', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)'] | 6/5/2022 16:51 | 1,530,000,000,000,000,000 | patients with ras wild-type metastatic crc benefit from panitumumab/mfolfox #crcsm #asco22 #oncology | Your online destination for Oncology Nursing news, clinical insights, and resources. | Company / Organization | Media / News |
paradigm | panitumumab | amgen,takeda | gi | 1 | ['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'paradigm'] | 6/5/2022 17:11 | 1,530,000,000,000,000,000 | paradigm will not be the final answer for ras wild-type crc: there is a clear violation of non-proportional hazards premise, and survival estimates based either on km or cox regression do not hold.#asco2022 #paradigm | M.D., Sc.D., oncologist, champion of universal access to cancer prev & treat. Opinion my own, RT = support/endorsement. | Individual | HCP |
improve | panitumumab | amgen,takeda | gi | 1 | ['colorectal', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'crcsm', 'improve ', 'panitumumab', 'rectal'] | 6/6/2022 10:54 | 1,530,000,000,000,000,000 | randomized intermittent or continuous panitumumab plus folfiri (folfiri/pani) for first-line treatment of patients (pts) with ras/braf wild-type (wt) metastatic colorectal cancer (mcrc): the improve study. talk by dr. antonio avallone, md #asco22 #crcsm | Pt Adv, NCI Rectal Anal TF
Mom, lifelong learner
Wants to bring patient voice to research, clinical trials & more!
Check out @CRCTrialsChat
1st love: Virology | Individual | Advocacy / Charity |
improve | panitumumab | amgen,takeda | gi | 1 | ['colorectal', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'crcsm', 'improve ', 'panitumumab', 'rectal'] | 6/6/2022 10:57 | 1,530,000,000,000,000,000 | randomized intermittent or continuous panitumumab plus folfiri (folfiri/pani) for first-line treatment of patients (pts) with ras/braf wild-type (wt) metastatic colorectal cancer (mcrc): the improve study. talk by dr. antonio avallone, md #asco22 #crcsm | Pt Adv, NCI Rectal Anal TF
Mom, lifelong learner
Wants to bring patient voice to research, clinical trials & more!
Check out @CRCTrialsChat
1st love: Virology | Individual | Advocacy / Charity |
improve | panitumumab | amgen,takeda | gi | 1 | ['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'improve '] | 6/6/2022 10:58 | 1,530,000,000,000,000,000 | dr. avallone w/ the improve study: intermittent vs continuous folfiri/pani for 1l ras/braf wt mcrc. 83-85% l sided tumors. pfsot (on treatment) was 12.6 vs 17.6 months with 1 year pfsot of 51.7 vs 61.3%. looks like l sided benefits, r does not. #asco22 | Gastrointestinal medical oncology, cancer of unknown primary, and value-based cancer care delivery. Tweets mine. | Individual | HCP |
improve | panitumumab | amgen,takeda | gi | 1 | ['colorectal', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'crcsm', 'improve ', 'panitumumab', 'rectal'] | 6/6/2022 10:59 | 1,530,000,000,000,000,000 | randomized intermittent or continuous panitumumab plus folfiri (folfiri/pani) for first-line treatment of patients (pts) with ras/braf wild-type (wt) metastatic colorectal cancer (mcrc): the improve study. talk by dr. antonio avallone, md #asco22 #crcsm very interesting.. | Pt Adv, NCI Rectal Anal TF
Mom, lifelong learner
Wants to bring patient voice to research, clinical trials & more!
Check out @CRCTrialsChat
1st love: Virology | Individual | Advocacy / Charity |
improve | panitumumab | amgen,takeda | gi | 1 | ['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'improve '] | 6/6/2022 10:59 | 1,530,000,000,000,000,000 | improve phase-ii in ras/braf wt crc 8 cycle folfiri/pani -> break until progression -> folfiri/pani vs continuous folfiri/pani
similar treatment exposure, dcr 94% vs 90%,
pfs 20.2 vs 13.2 left-sided, but 7.9 vs 10 re-sided interesting for left sided crc --> phase-3? | Physician-scientist, focussed on translational research in hepatobiliary cancer and precision medicine | Individual | HCP |
paradigm | panitumumab | amgen,takeda | gi | 1 | ['colorectal', 'panitumumab', 'rectal'] | 6/6/2022 12:34 | 1,530,000,000,000,000,000 | panitumumab plus mfolfox6 improves overall survival in a type of newly diagnosed metastatic colorectal cancer - the asco post | Oncólogo clínico
IDC Las Américas - AUNA | Individual | Professional |
improve | panitumumab | amgen,takeda,aura biosciences | gi | 1 | ['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'improve ', 'panitumumab', 'aura '] | 6/6/2022 11:02 | 1,530,000,000,000,000,000 | #asco22 oral abstract session panitumumab + folfiri in ras/braf wt mcrc improve study dr. antonio avallone intermittent administration has less ae's and promising in left-sided mcrc | Independent Medical Affairs Advisor & Research/Patient Advocate. metastatic colon cancer survivor diagnosed 2003 NED since 2006.
FCOI: https://t.co/cRjnIJrYKm | Individual | HCP |
Not Tagged | ponatinib,blinatumomab | amgen,takeda,incyte,otsuka,astellas | myeloid | 1 | ['ph+ all', 'ponatinib', 'blinatumomab'] | 6/4/2022 8:59 | 1,530,000,000,000,000,000 | #asco #chemo-free ponatinib plus blinatumomab for adult pts with new ph+ all led to 93% 2yr survival. no more bad hair days! | Cancer specialist searching the world for better therapy | Individual | HCP |
Not Tagged | ponatinib,blinatumomab | amgen,takeda,incyte,otsuka,astellas | myeloid | 1 | ['ponatinib', 'cml', 'leukemia', 'blinatumomab', 'leusm'] | 6/4/2022 15:11 | 1,530,000,000,000,000,000 | congress #asco22 | reports on a phase ii study of ponatinib + blinatumomab in pts with either nd ph+all, r/r ph+all or cml. (n=55) 96% nd all pts achieved cr/cri and of the r/r ph+all pts 92% achieved cr/cri and 83% in cml pts #leusm #leukemia | A global education platform providing clinical updates on acute lymphoblastic leukemia. #leusm #allsm | Company / Organization | Healthcare |
paradigm | panitumumab,bevacizumab | amgen,takeda,roche | gi | 1 | ['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)'] | 6/5/2022 13:51 | 1,530,000,000,000,000,000 | #asco22: modest os advantage (37.9vs34.3mo) and depth of response with 1st line pmab vs bev folfox in left raswt mcrc. my questions: why age 80+ excluded? will patients accept the greater toxicity? will this change practice? | Med Director GI Oncology @ProvHealth @ChilesResearch, SWOG Rectal-Anal Cancer Co-Chair, NCI GSC Member, #colorectalcancer #NETs. Cycling & ski enthusiast! | Individual | HCP |
Not Tagged | panitumumab,bevacizumab | amgen,takeda,roche | Not Tagged | 1 | [] | 6/6/2022 6:13 | 1,530,000,000,000,000,000 | now, pmab vs bev in left sided ras wt colon cancer - 36+ months median survival. but looking at curves, despite positive trial, i am not that impressed. curves are together/criss-cross until around/at 30 months i think we need to discuss this one #asco22 | Chief MedOnc @SylvesterCancer. Helping improve Cancer Control in LMICs. Editor-in-Chief @JCOGO_ASCO, Board Member @UICC - co-chair #ATOMcoalition | Individual | HCP |
paradigm | panitumumab,bevacizumab | amgen,takeda,roche | gi | 1 | ['paradigm'] | 6/5/2022 14:05 | 1,530,000,000,000,000,000 | important question on paradigm data: why a targeted therapy struggles to prove superiority against bev? we need to understand biology since it seems that egfr pathway inhibition is significant only in a minority of raswt pts. #asco22 | ??????????? ??? ????????. Passionate and perfectionist. Med Onc with special love to Gyn Onc and prostate cancer. | Individual | HCP |
paradigm | panitumumab,bevacizumab | amgen,takeda,roche | gi | 1 | ['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'paradigm'] | 6/5/2022 14:56 | 1,530,000,000,000,000,000 | ph 3 paradigm trial: folfox-pani v folfox-bev as 1l treatment in ras wt mcrc left-sided tumors treated w/ pani had: os (37.9 v 34.3, hr 0.82) orr (80% v 68%) r0 resection (18% v 11%) not exactly a practice changing study... but no doubt left some thoughts #asco22 | ??Medical Oncologist, MSc, PhD. GI/neuroendocrine/GU tumors/breast cancer ??Hospital Universitario UFC-CE, Oncologia D’Or | Individual | HCP |
paradigm | panitumumab,bevacizumab | amgen,takeda,roche | gi | 1 | ['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'paradigm'] | 6/5/2022 13:38 | 1,530,000,000,000,000,000 | outstanding discussion by dr. cremolini of #mcrc paradigm trial. do you agree with her treatment algorithm of folfoxiri-bev for pts with kras-mt left-sided tumors? #asco2022 | Oncologist. SVP Medical Informatics @Change_HC. Adjunct Professor @DukeMedSchool. Photographer. Trying to survive w/o travel (and failing). | Individual | HCP |
paradigm | panitumumab,bevacizumab | amgen,takeda,roche | gi | 1 | ['panitumumab'] | 6/5/2022 13:13 | 1,530,000,000,000,000,000 | dr. yoshino lba1 #asco22: discontinuation rate for panitumumab was 23.8% vs. 18.4% for bev | Oncologist & Chief Medical Science Officer @ASCO #CancerLinQ. Classical/choral music fan ???? https://t.co/GxpBhxmsFj. RT or like may mean I agree; or not. Tweets=only moi | Individual | Professional |
paradigm | panitumumab,bevacizumab | amgen,takeda,roche | gi | 1 | ['panitumumab', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'paradigm'] | 6/5/2022 13:33 | 1,530,000,000,000,000,000 | paradigm results out! folfox plus panitumumab superior to folfox plus bev in the ras wild type metastatic crc pts. pfs similar in the two groups. #asco2022 | Breast cancer specialist. Shoe lover. Cupcake connoisseuse. Opinions are my own, RTs not an endorsement. | Individual | HCP |
Not Tagged | panitumumab,bevacizumab | amgen,takeda,roche | gi | 1 | ['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)'] | 6/5/2022 13:42 | 1,530,000,000,000,000,000 | #asco2022 #mlmasco - japanese trial: improved os in left-sided wtras-mcrc with pani-folfox vs bev-folfox in 1l. dr. cremolini s (discussant) algorithm | "What we cannot speak about we must pass over in silence" (L. Wittgenstein) | Individual | Blogger / Random / Other |
Not Tagged | panitumumab,bevacizumab | amgen,takeda,roche | Not Tagged | 1 | ['vectibix'] | 6/5/2022 14:25 | 1,530,000,000,000,000,000 | it seems to me like arguing about angels on the head of a pin. in ras wild type first line you have two choices, bev or vectibix, doesn t matter in the long run what you choose. however, skin catastrophe with vec can traumatize the pt so much that they ll forever be shy. | Dr T’s Sportfax, The most exclusive Sportgroup on the continent. Shycollie Racing, hand-made precision fuel injectors for endurance motorsports. Medicine. | Individual | Blogger / Random / Other |
ramp 203 | avutometinib,sotorasib,vs-6766 | amgen,verastem | thoracic | 1 | ['sclc', 'lung', 'ramp 203', 'vs-6766', 'sotorasib', 'nsclc'] | 6/6/2022 7:45 | 1,530,000,000,000,000,000 | dr. govindan's poster (#122) on a phase 1/2 study of vs-6766 (raf/mek clamp) in combination with sotorasib (g12c inhibitor) in patients with kras g12c mutant non small cell lung cancer (nsclc) (ramp 203) will be available in hall a at 8:00am. #asco22 | A National Cancer Institute Comprehensive Cancer Center and member of the National Comprehensive Cancer Network | Company / Organization | Pharma / Biotech |
prince | paclitaxel,sotigalimab,nivolumab | apexigen,bms | other,other | 1 | ['prince', 'nivo', 'nivolumab', 'sotigalimab', 'pancreatic'] | 6/3/2022 16:47 | 1,530,000,000,000,000,000 | in for #asco22
sotigalimab and/or nivolumab with chemotherapy in first-line metastatic #pancreaticcancer: clinical and immunologic analyses from the randomized phase 2 prince trial | Pancreatic cancer researcher and GI pathologist. Striving to improve the lives of patients with cancer. | Individual | HCP |
prince | paclitaxel,sotigalimab,nivolumab | apexigen,bms | other,other | 1 | ['nivolumab', 'prince', 'pancreatic', 'nivo', 'sotigalimab', 'apexigen'] | 6/6/2022 8:05 | 1,530,000,000,000,000,000 | apexigen announces nature medicine publication and asco presentation on the phase 2 prince trial showcasing distinct biosignatures in metastatic pancreatic cancer patients treated with sotigalimab and/or nivolumab in combination with chemotherapy - data... | CEO Of Digital Media Online | Individual | Media / News |
prince | paclitaxel,sotigalimab,nivolumab | apexigen,bms | other,other | 1 | ['nivolumab', 'prince', 'pancreatic', 'nivo', 'sotigalimab', 'apexigen'] | 6/6/2022 8:05 | 1,530,000,000,000,000,000 | apexigen announces nature medicine publication and asco presentation on the phase 2 prince trial showcasing distinct biosignatures in metastatic pancreatic cancer patients treated with sotigalimab and/or nivolumab in combination with chemotherapy - data... | CEO Of Digital Media Online | Individual | Media / News |
prince | paclitaxel,sotigalimab,nivolumab | apexigen,bms | other | 1 | ['prince', 'apexigen'] | 6/6/2022 11:35 | 1,530,000,000,000,000,000 | apexigen announces nature medicine publication and asco presentation on the phase 2 prince trial showcasing distinct biosignatures in metastatic pan.. $bcac | Run by investors, for investors.
Real-time:
PRs
Gov. contract awards
Earnings
M&As
FDA approvals
Insider trades
SEC filings
And more
Not investment advice | Bot / Aggregator | Finance / Investment |
prince | paclitaxel,sotigalimab,nivolumab | apexigen,bms | other,other | 1 | ['nivolumab', 'prince', 'pancreatic', 'nivo', 'sotigalimab'] | 6/6/2022 13:00 | 1,530,000,000,000,000,000 | apexigen announces nature medicine publication and asco presentation on the phase 2 prince trial showcasing distinct biosignatures in metastatic pancreatic cancer patients treated with sotigalimab and/or nivolumab in combination with chemotherapy | We provide a balanced view on small cap biotech equities. | Company / Organization | Finance / Investment |
Not Tagged | Not Tagged | aravive | gu,gi | 1 | ['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'rcc,(-irccs),(-srcc),(-urcc)', 'aravive'] | 6/4/2022 3:27 | 1,530,000,000,000,000,000 | would love to get reactions to #aravive inc. crcc data. i think it looks phenomenal and provides proof of concept that gas6 inhibition of axl triggering could be a multi indication solution for matasticis! very exciting (non toxic agent, ideal adjunct!) | Retired from financial services | Individual | Finance / Investment |
Not Tagged | batiraxcept | aravive | thoracic | 1 | ['batiraxcept', 'nsclc', 'sclc'] | 6/5/2022 22:07 | 1,530,000,000,000,000,000 | very excited for mech of action.
hoping batiraxcept will be tried in alk+ nsclc someday, bc that cancer goes to brain due to activation of axl and avaliable tki's are not high affinity to axl | Retired from financial services | Individual | Finance / Investment |
not tagged | not tagged | aravive | not tagged | 1 | ['$arav'] | 6/7/2022 3:00 | 1,530,000,000,000,000,000 | axl pathway should be another puzzle on target therapy. $arav | null | Individual | Blogger / Random / Other |
Not Tagged | Not Tagged | arcellx | Not Tagged | 1 | ['car-t', '$aclx'] | 6/5/2022 11:38 | 1,530,000,000,000,000,000 | promising results reported for new generation of car-t immunotherapy for myeloma via #asco22 oricell, $aclx $grcl | Reporter @statnews. I am the Night King of biotech. Data Are. Dog ??er. '21 Polk Award winner. Said one analyst: The likes of Adam Feuerstein attack viciously. | Individual | Media / News |
Not Tagged | Not Tagged | arcellx | Not Tagged | 1 | ['thanks', 'car-t', 'arcellx', '$aclx'] | 6/3/2022 15:49 | 1,530,000,000,000,000,000 | gene&cell therapy >> #asco22: unconcerned with later market entry, arcellx on the up with new bcma car-t data: arcellx $aclx has been trading up more than 25% in the last five days, thanks to an asco abstract for its #lucidquest #genetherapy #celltherapy | Strategy & Competitive Marketing | Digital & Social Pharma | Life Sciences Investment | Cell & Gene Therapy | Vaccines | Individual | Finance / Investment |
ARC-101 Arm1 | Not Tagged | arcellx | Not Tagged | 1 | ['cart,(-cartitude)', 'arcellx'] | 6/4/2022 9:16 | 1,530,000,000,000,000,000 | join arcellx management/clinician experts, sunday, june 5th at 7 pm cdt, for a presentation and q&a of clinical data for our cart-ddbcma phase 1 expansion clinical trial. watch the live webcast or replay: #asco22 | We are a clinical-stage biotechnology company reimagining cell therapy through the development of innovative immunotherapies. | Company / Organization | Pharma / Biotech |
ARC-101 Arm1 | Not Tagged | arcellx | Not Tagged | 1 | ['cart,(-cartitude)', 'arcellx'] | 6/4/2022 18:32 | 1,530,000,000,000,000,000 | dr. matthew frigault ( ) is presenting new clinical data from our cart-ddbcma phase 1 extension study in an oral presentation at #asco22 tomorrow morning at 9:10 am cdt. read the full pr here: #arcellx | We are a clinical-stage biotechnology company reimagining cell therapy through the development of innovative immunotherapies. | Company / Organization | Pharma / Biotech |
Not Tagged | Not Tagged | arcellx | multiple myeloma | 1 | ['car-t', 'mmsm', '$aclx'] | 6/5/2022 12:10 | 1,530,000,000,000,000,000 | companies oricell $aclx are testing the next gen of car-t therapy for myeloma - but as a note one of the v interesting things are the technologies that will speed up car-t production time $grcl and others #mmsm #asco22 | undignified, unfunny, unaward-winning journalist doing health + cancer @STATNews. by: @wbur @npr @sciam @wnyc |PGP key @ https://t.co/bN1GBY0wLX| English:Español:?? | Individual | Media / News |
ARC-101 Arm1 | Not Tagged | arcellx | Not Tagged | 1 | ['cart,(-cartitude)', 'arcellx'] | 6/5/2022 15:15 | 1,530,000,000,000,000,000 | tune into arcellx management and clinician experts, tonight at 7 pm cdt, for a presentation and discussion of clinical data for our cart-ddbcma phase 1 expansion clinical trial. watch the live webcast or replay: #asco22
#arcellx | We are a clinical-stage biotechnology company reimagining cell therapy through the development of innovative immunotherapies. | Company / Organization | Pharma / Biotech |
ARC-101 Arm1 | Not Tagged | arcellx | multiple myeloma | 1 | ['multiple myeloma', 'cart,(-cartitude)', 'arcellx', '$aclx'] | 6/3/2022 15:00 | 1,530,000,000,000,000,000 | $aclx arcellx presents continued robust long-term responses from its cart-ddbcma phase 1 expansion trial in patients with relapsed or refractory multiple myeloma at the 2022 asco annual meeting | Free Stock Market News are delayed 15 sec. Full features and live news available here: https://t.co/fWRacb3Vft | Bot / Aggregator | Finance / Investment |
ARC-101 Arm1 | Not Tagged | arcellx | multiple myeloma | 1 | ['multiple myeloma', 'cart,(-cartitude)', 'arcellx', '$aclx'] | 6/3/2022 15:01 | 1,530,000,000,000,000,000 | $aclx arcellx presents continued robust long-term responses from its cart-ddbcma phase 1 expansion trial in patients with relapsed or refractory multiple myeloma at the 2022 asco annual meeting stock news alerts in bio | Over 500 members. DM us for our premium stock alerts. | Bot / Aggregator | Finance / Investment |
ARC-101 Arm1 | Not Tagged | arcellx | multiple myeloma | 1 | ['multiple myeloma', 'cart,(-cartitude)', 'arcellx', '$aclx'] | 6/3/2022 15:01 | 1,530,000,000,000,000,000 | $aclx arcellx presents continued robust long-term responses from its cart-ddbcma phase 1 expansion trial in patients with relapsed or refractory multiple myeloma at the 2022 asco annual meeting | null | Bot / Aggregator | Finance / Investment |
ARC-101 Arm1 | Not Tagged | arcellx | Not Tagged | 1 | ['cart,(-cartitude)', 'arcellx'] | 6/3/2022 15:06 | 1,530,000,000,000,000,000 | arcellx presents continued robust long-term responses from its cart-ddbcma phase 1 expansion trial in patients with | null | Bot / Aggregator | Finance / Investment |
ARC-101 Arm1 | Not Tagged | arcellx | multiple myeloma | 1 | ['multiple myeloma', 'cart,(-cartitude)', 'arcellx', '$aclx'] | 6/3/2022 15:07 | 1,530,000,000,000,000,000 | $aclx [15s. delayed]: issued press release on june 03, 16:00:00: arcellx presents continued robust long-term responses from its cart-ddbcma phase 1 expansion trial in patients with relapsed or refractory multiple myeloma at the 2022 asco annual meeting | Flash Alert is a low-latency financial news service which sources SEC, press releases, credible news sources to get your news about stocks in near real-time | Bot / Aggregator | Finance / Investment |
ARC-101 Arm1 | Not Tagged | arcellx | multiple myeloma | 1 | ['multiple myeloma', 'cart,(-cartitude)', 'arcellx', '$aclx'] | 6/3/2022 15:33 | 1,530,000,000,000,000,000 | $aclx: arcellx presents continued robust long-term responses from its cart-ddbcma phase 1 expansion trial in patients with relapsed or refractory multiple myeloma at the 2022 asco annual meeting | The information in these Market Commentaries do not constitute a solicitation of the purchase or sale of any stocks , or options contracts. | Bot / Aggregator | Finance / Investment |
Not Tagged | Not Tagged | arcellx | Not Tagged | 1 | ['car-t', 'arcellx', '$aclx'] | 6/3/2022 15:42 | 1,530,000,000,000,000,000 | #asco22: unconcerned with later market entry, arcellx on the up with new bcma car-t data
by $aclx | Founder, EIC of Endpoints News: The biopharma world is here -- 144,000 global industry subscribers. We work for it. #sweatequity john@endpointsnews.com | Individual | Publication / Journal |
ARC-101 Arm1 | Not Tagged | arcellx | multiple myeloma | 1 | ['multiplemyeloma', 'cart,(-cartitude)', '$aclx', 'arcellx'] | 6/4/2022 7:56 | 1,530,000,000,000,000,000 | #arcellx presents continued robust long-term responses from its #cartddbcma phase 1 expansion trial in patients with #relapsed or #refractory #multiplemyeloma at the #asco22 annual meeting $aclx | Follow top-line development in the oncology commercial domain. Gain entry to KOL discussions, including both medical professionals and business leaders. | Company / Organization | Healthcare |
ARC-101 Arm1 | Not Tagged | arcellx | multiple myeloma | 1 | ['multiple myeloma', 'cart,(-cartitude)', 'arcellx'] | 6/5/2022 8:08 | 1,530,000,000,000,000,000 | arcellx presents continued robust long-term responses from its cart-ddbcma phase 1 expansion trial in patients with relapsed or refractory multiple myeloma at the 2022 asco annual meeting | Liquidyne is a leader in single-use and sanitary process equipment for fluid transfer, measurement, and control. | Company / Organization | Pharma / Biotech |
Not Tagged | Not Tagged | arcellx | Not Tagged | 1 | ['$aclx'] | 6/5/2022 9:18 | 1,530,000,000,000,000,000 | $aclx very difficult to treat population. #asco22 | PharmD, MBA ?? | Individual | HCP |
ARC-101 Arm1 | Not Tagged | arcellx | Not Tagged | 1 | ['cart,(-cartitude)', 'arcellx'] | 6/5/2022 20:05 | 1,530,000,000,000,000,000 | interviews dr. matthew frigault ( ), administrative director, cellular therapy service at , regarding clinical data from the arcellx cart-ddbcma phase 1 trial. watch the interview now: #asco22
#arcellx | We are a clinical-stage biotechnology company reimagining cell therapy through the development of innovative immunotherapies. | Company / Organization | Pharma / Biotech |
ARC-101 Arm1 | not tagged | arcellx | multiple myeloma | 1 | ['multiple #myeloma', 'cart,(-cartitude)', 'arcellx'] | 6/7/2022 16:00 | 1,530,000,000,000,000,000 | investigational #cartcell therapy from continues to produce impressive response rates while showing durability for patients with advanced multiple #myeloma read more about the results presented at #asco22 here: | The content you need, when you need it. | Bot / Aggregator | Media / News |
ARC-101 Arm1 | not tagged | arcellx | multiple myeloma | 1 | ['multiple #myeloma', 'cart,(-cartitude)', 'arcellx'] | 6/7/2022 15:01 | 1,530,000,000,000,000,000 | investigational #cartcell therapy from continues to produce impressive response rates while showing durability for patients with advanced multiple #myeloma read more about the results presented at #asco22 here: | The content you need, when you need it. | Bot / Aggregator | Media / News |
Not Tagged | Not Tagged | arcellx,ayala pharma | myeloid | 1 | ['congrat', 'aml,(-streamline),(-seamless),(-kamloops)', '$aclx', '$ayla', 'biotec'] | 6/4/2022 0:05 | 1,530,000,000,000,000,000 | #asco22 forget a few:
1. $aclx data is good. do i care? i don't know. maybe i do. maybe i don't. 2. $ayla getting the gsi treatment. bearish on gsis. 3. was pleased to see $amlx extension. my mind didn't fully process possibility of extension. +26%. congrats to those holding! | Biotech, Healthcare, Investing, Philosophy, More | Not Investment Advice | Will Make Mistakes, Always Learning | Looking For Next Seat | DMs Open | Bot / Aggregator | Finance / Investment |
not tagged | not tagged | arcellx,janssen | not tagged | 1 | ['arcellx', 'fierce', '$aclx'] | 6/7/2022 9:37 | 1,530,000,000,000,000,000 | arcellx's car-modified t-cell therapy seems to have come out on top of the market-leading med by j&j and legend biotech $aclx | Tweets by the Fierce Life Sciences editorial team. Subscribe to our daily email newsletter at https://t.co/7Q6gUQgCIU | Company / Organization | Media / News |
not tagged | not tagged | arcus biosciences | not tagged | 1 | ['arcus biosciences'] | 6/6/2022 9:11 | 1,530,000,000,000,000,000 | we're excited to be at in chicago for #asco22! drop by booth #26117 and discover how #arcusbio is helping to advance cancer innovation. | At the forefront of designing novel combination medicines in the pursuit of cures for people living with cancer. View our guidelines: https://t.co/mP1hLQhaZ3 | Company / Organization | Pharma / Biotech |
not tagged | not tagged | arcus biosciences | not tagged | 1 | ['arcus biosciences'] | 6/7/2022 9:00 | 1,530,000,000,000,000,000 | as #asco22 comes to a close, we want to thank all those who keep pushing the boundaries of #oncology research. join us in our pursuit of advancing #cancerresearch and learn more about our ongoing #clinicaltrials: | At the forefront of designing novel combination medicines in the pursuit of cures for people living with cancer. View our guidelines: https://t.co/mP1hLQhaZ3 | Company / Organization | Pharma / Biotech |
not tagged | not tagged | arcus biosciences,roche | not tagged | 1 | ['roche,(-broche),(-rocheter)', '$rcus'] | 6/7/2022 18:52 | 1,530,000,000,000,000,000 | is there any hope for $rcus?
roche keeps the faith in new cancer immunotherapy despite trial setbacks via | null | Individual | Finance / Investment |
Not Tagged | dcvax-l | ardelyx,northwest biotherapeutics | other | 1 | ['gbm', 'biotec'] | 6/3/2022 19:05 | 1,530,000,000,000,000,000 | $labu $ardx $nwbo great day for me. biggest position a monster. monday could be strong for #nwbo following presentation tomorrow at #asco22 for #gbm with #dcvax | BioPharma Investor $LABU $NWBO $ARDX -Identify PBKAC & Capitalize. All Tweets are my opinion and not investment advice. | Individual | Finance / Investment |
not tagged | crenolanib | arog | myeloid,gi | 1 | ['leusm', 'leukemia', 'crenolanib', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'aml,(-streamline),(-seamless),(-kamloops),(-dreamlike)', 'aml,(-streamline),(-seamless),(-kamloops),(-latamleaders)'] | 6/7/2022 12:21 | 1,530,000,000,000,000,000 | congress #asco22 | presents the results of a phase ii trial of crenolanib + 7+3 in nd flt3 aml. (n=44) overall crc (cr + cri) was 73% after 1 induction cycle; 86% after two cycles. mrd-ve crc was achieved in 16 evaluable younger pts #leusm #leukemia | The AML Hub is an evidence-based online resource on Acute Myeloid Leukemia (AML), for academic researchers and treating clinicians. #leusm | Company / Organization | Healthcare |
not tagged | crenolanib,trastuzumab deruxtecan | arog,daiichi sankyo,astrazeneca | myeloid | 1 | ['crenolanib', 'aml,(-streamline),(-seamless),(-kamloops),(-dreamlike)', 'aml,(-streamline),(-seamless),(-kamloops),(-latamleaders)'] | 6/7/2022 10:05 | 1,530,000,000,000,000,000 | at #asco22? at 11:57 a.m. cdt, in hall s, room 100a, eunice wang, md, will present the results of a phase 2 clinical trial combining crenolanib with standard intensive chemotherapy for treatment of adults with newly diagnosed flt3-mutant aml. learn more: | Roswell Park brings together the best medical & scientific minds in cancer care. We are the only NCI-designated comprehensive cancer center in Upstate New York. | Company / Organization | Hospital / Clinic |
Not Tagged | transcon | ascendis pharma | Not Tagged | 1 | ['transcon', 'ascendispharma'] | 6/3/2022 14:12 | 1,530,000,000,000,000,000 | the ascendis team is attending #asco2022, where we ll share our transcon il-2 / preclinical data and #clinicaltrial in progress. see you in chicago! | Ascendis Pharma is applying its innovative TransCon™ technology to build a leading biopharma company focused on making a difference in patients’ lives. | Company / Organization | Pharma / Biotech |
Not Tagged | olverembatinib | ascentage pharmaceuticals | gi | 1 | ['olverembatinib'] | 6/6/2022 23:35 | 1,530,000,000,000,000,000 | dcbn news: asco 2022 | the first dataset of olverembatinib (hqp1351) in patients with gist demonstrates therapeutic potential with a clinical benefit rate of 83.3%: suzhou, china, and rockville, md., june ... #biotech #news | Life science news and jobs from Washington DC, Maryland and Virginia. Part of @BiotechNetworks, connecting #biotech since 2008. | Company / Organization | Media / News |
Not Tagged | olverembatinib | ascentage pharmaceuticals | gi | 1 | ['olverembatinib'] | 6/6/2022 23:09 | 1,530,000,000,000,000,000 | asco 2022 | the first dataset of olverembatinib (hqp1351) in patients with gist demonstrates therapeutic potential with a clinical benefit rate of 83.3% | World News Guru is completely free and offers a broad range of media content from a varied and extensive range of sources. | Bot / Aggregator | Blogger / Random / Other |
Not Tagged | olverembatinib | ascentage pharmaceuticals | gi | 1 | ['olverembatinib'] | 6/6/2022 23:15 | 1,530,000,000,000,000,000 | asco 2022 | the first dataset of olverembatinib (hqp1351) in patients with gist | World News Guru is completely free and offers a broad range of media content from a varied and extensive range of sources. | Bot / Aggregator | Blogger / Random / Other |
Not Tagged | olverembatinib | ascentage pharmaceuticals | gi | 1 | ['olverembatinib'] | 6/6/2022 23:18 | 1,530,000,000,000,000,000 | asco 2022 | the first dataset of olverembatinib (hqp1351) in patients with gist demonstrates therapeutic potential w | null | Bot / Aggregator | Finance / Investment |
Not Tagged | alrizomadlin | ascentage pharmaceuticals | not tagged | 1 | ['ascent', 'alrizomadlin', 'ascentage pharma', 'ascentage'] | 6/6/2022 23:18 | 1,530,000,000,000,000,000 | asco 2022 | ascentage pharma releases updated results demonstrating the therapeutic potential of alrizomadlin (apg-1 | null | Bot / Aggregator | Finance / Investment |
Not Tagged | olverembatinib | ascentage pharmaceuticals | gi | 1 | ['olverembatinib'] | 6/6/2022 23:45 | 1,530,000,000,000,000,000 | asco 2022 | the first dataset of olverembatinib (hqp1351) in patients with gist demonstrates therapeutic potential with a clinical benefit rate of 83.3% | Politics around the globe | Company / Organization | Media / News |
not tagged | not tagged | ascentage pharmaceuticals | not tagged | 1 | ['ascent', 'ascentage pharma', 'ascentage'] | 6/7/2022 21:51 | 1,530,000,000,000,000,000 | (asco 2022 | ascentage pharma releases for the first time results of its fak/alk/ros1 ) has been published on the globe - | null | Unknown / Deleted | Unknown / Deleted |
not tagged | lisaftoclax | ascentage pharmaceuticals | lymphoma | 1 | ['apg-2575', 'ascent', 'cll', 'lisaftoclax', 'ascentage pharma', 'ascentage'] | 6/7/2022 20:35 | 1,530,000,000,000,000,000 | dcbn news: asco 2022 | ascentage pharma releases updated data demonstrating lisaftoclax's (apg-2575) therapeutic potential in patients with r/r cll/sll: suzhou, china and rockville, md., june 7, ... #biotech #news | Life science news and jobs from Washington DC, Maryland and Virginia. Part of @BiotechNetworks, connecting #biotech since 2008. | Company / Organization | Media / News |
not tagged | apg-2449 | ascentage pharmaceuticals | thoracic | 1 | ['ascent', 'sclc', 'nsclc', 'apg-2449 ', 'ascentage pharma', 'ascentage'] | 6/7/2022 20:35 | 1,530,000,000,000,000,000 | dcbn news: asco 2022 | ascentage pharma releases for the first time results of its fak/alk/ros1 inhibitor apg-2449 demonstrating safety and efficacy in patients with advanced nsclc: suzhou, china, and ... #biotech #news | Life science news and jobs from Washington DC, Maryland and Virginia. Part of @BiotechNetworks, connecting #biotech since 2008. | Company / Organization | Media / News |
not tagged | lisaftoclax | ascentage pharmaceuticals | not tagged | 1 | ['apg-2575', 'ascent', 'lisaftoclax', 'ascentage pharma', 'ascentage'] | 6/7/2022 20:25 | 1,530,000,000,000,000,000 | asco 2022 | ascentage pharma releases updated data demonstrating lisaftoclax's (apg-2575) therapeutic potential in p | null | Bot / Aggregator | Finance / Investment |
not tagged | apg-2449 | ascentage pharmaceuticals | not tagged | 1 | ['ascent', 'apg-2449 ', 'ascentage pharma', 'ascentage'] | 6/7/2022 20:25 | 1,530,000,000,000,000,000 | asco 2022 | ascentage pharma releases for the first time results of its fak/alk/ros1 inhibitor apg-2449 demonstratin | null | Bot / Aggregator | Finance / Investment |
not tagged | lisaftoclax | ascentage pharmaceuticals | lymphoma | 1 | ['apg-2575', 'ascent', 'cll', 'lisaftoclax', 'ascentage pharma', 'ascentage'] | 6/7/2022 19:47 | 1,530,000,000,000,000,000 | asco 2022 | ascentage pharma releases updated data demonstrating lisaftoclax s (apg-2575) therapeutic potential in patients with r/r cll/sll #stocksmarket #pressrelease | Join us at https://t.co/9QZSYoqhvl - Stock Market News and Press Releases. #StockMarket - As an affiliate, we earn from qualifying purchases. | Bot / Aggregator | Finance / Investment |
not tagged | olverembatinib | ascentage pharmaceuticals | gi | 1 | ['olverembatinib', '#gi'] | 6/7/2022 3:55 | 1,530,000,000,000,000,000 | the first dataset of #olverembatinib (#hqp1351) in patients with #gist demonstrates therapeutic potential with a clinical benefit rate of 83.3% | Follow top-line development in the oncology commercial domain. Gain entry to KOL discussions, including both medical professionals and business leaders. | Company / Organization | Healthcare |
not tagged | olverembatinib | ascentage pharmaceuticals | not tagged | 1 | ['ascent', 'olverembatinib', 'ascentage pharma', 'ascentage'] | 6/7/2022 3:24 | 1,530,000,000,000,000,000 | asco 2022 | the first dataset of olverembatinib (hqp1351) in patients with gist demonstrates therapeutic potential with a clinical benefit rate of 83.3% ascentage pharma announced that it has released the latest results from a phase ib/ii study of the | All things biotech. | Bot / Aggregator | Media / News |
not tagged | olverembatinib | ascentage pharmaceuticals | not tagged | 1 | ['ascent', 'olverembatinib', 'ascentage pharma', 'ascentage'] | 6/7/2022 3:24 | 1,530,000,000,000,000,000 | asco 2022 | the first dataset of olverembatinib (hqp1351) in patients with gist demonstrates therapeutic potential with a clinical benefit rate of 83.3% ascentage pharma announced that it has released the latest results from a phase ib/ii study of the | null | Bot / Aggregator | Media / News |
not tagged | olverembatinib | ascentage pharmaceuticals | not tagged | 1 | ['ascent', 'olverembatinib', 'ascentage pharma', 'ascentage'] | 6/7/2022 2:54 | 1,530,000,000,000,000,000 | asco 2022 | the first dataset of olverembatinib (hqp1351) in patients with gist demonstrates therapeutic potential with a clinical benefit rate of 83.3% ascentage pharma announced that it has released the latest results from a phase ib/ii study of the | BioCalifornia is committed to the growth of life sciences, and commercialization of discoveries to improve human health, the environment, and sustainability. | Company / Organization | Healthcare |
Not Tagged | Not Tagged | aska pharmaceuticals | Not Tagged | 1 | ['dance', 'aska'] | 6/6/2022 19:47 | 1,530,000,000,000,000,000 | i will pay for you not to dance samba . but i ll take the caipirinhas. | Oncologist.Rock Musician. Grill Master. Awesome Dad. Proud Brazilian. Director, Lymphoma and CLL Program @novanthealth Tweets my own | Individual | HCP |
Not Tagged | Not Tagged | astellas | other,gi,other | 1 | ['bcsm', 'pancsm', 'gastric', 'astellasus', 'astellas'] | 6/4/2022 18:44 | 1,530,000,000,000,000,000 | today is a #gastrooncology kind of day for me at #asco22! sat in on a poster discussion on the latest in #gastrointestinalcancer and studied the #gastriccancer landscape . #stcsm #pancsm #hpbcsm #esocsm #ascodailynews #asco2022 #eczotwock and #psi . | Oncology Resident Physician, ECZ Otwock | Clinical Trial Specialist & Psycho-Oncologist, Zdrowie Zaczyna si? w G?owie | Medical Scientific Liaison, PSI CRO | Individual | HCP |
Not Tagged | Not Tagged | astellas | Not Tagged | 1 | ['astellas', 'astellasus'] | 6/3/2022 16:45 | 1,530,000,000,000,000,000 | that s a wrap on the first day of #asco22. we re thrilled to have colleagues back onsite alongside the #oncology community. if you re onsite, come see us at booth #10135. | A pharma company dedicated to changing tomorrow by improving the health of people around the world. Tweets for U.S. audience. Guidelines: https://t.co/AJlgiDgp38 | Company / Organization | Pharma / Biotech |
Not Tagged | Not Tagged | astellas | other | 1 | ['pancreatic', 'astellasus', 'astellas'] | 6/4/2022 8:41 | 1,530,000,000,000,000,000 | pancreatic cancer is a disease expected to be diagnosed in an estimated 62k people in the us this year alone. we re investigating new approaches for people impacted by this disease and are proud to share an update at #asco22. | A pharma company dedicated to changing tomorrow by improving the health of people around the world. Tweets for U.S. audience. Guidelines: https://t.co/AJlgiDgp38 | Company / Organization | Pharma / Biotech |
Not Tagged | Not Tagged | astellas | gu | 1 | ['prostate', 'astellasus', 'astellas'] | 6/5/2022 9:00 | 1,530,000,000,000,000,000 | we ve been exploring therapeutic approaches in advanced #prostatecancer for more than a decade, and there s still work to be done for those impacted for this disease. liz dalton shares an update from #asco22. | A pharma company dedicated to changing tomorrow by improving the health of people around the world. Tweets for U.S. audience. Guidelines: https://t.co/AJlgiDgp38 | Company / Organization | Pharma / Biotech |
Not Tagged | Not Tagged | astellas | Not Tagged | 1 | ['thank you', 'astellasus', 'astellas'] | 6/5/2022 14:13 | 1,530,000,000,000,000,000 | stop what you re doing and get to the booth at #asco22 right now amazing photo on latte by #buzzimpressions (oh and thank you for saving lives astellas onc ) | Author of “Full Circle: How Politics, Depression, and Yoga Helped Me Crush Colorectal Cancer and Crisis” | Individual | Advocacy / Charity |
not tagged | not tagged | astellas | not tagged | 1 | ['astellasus', 'astellas'] | 6/6/2022 9:00 | 1,530,000,000,000,000,000 | our passion for people and our innovative science drive us forward in our mission to change lives of those impacted by cancer. #asco22 | A pharma company dedicated to changing tomorrow by improving the health of people around the world. Tweets for U.S. audience. Guidelines: https://t.co/AJlgiDgp38 | Company / Organization | Pharma / Biotech |
Not Tagged | Not Tagged | astellas | gi | 1 | ['gastric', 'astellasus', 'astellas'] | 6/6/2022 17:21 | 1,530,000,000,000,000,000 | who says you can t be both on an island (literally) and at asco at the same time?!?! #gastriccancer #asco22 | null | Individual | Research / Science |
not tagged | not tagged | astellas | not tagged | 1 | ['in-person', 'astellasus', 'astellas'] | 6/7/2022 17:00 | 1,530,000,000,000,000,000 | as we wrap up #asco22, we re reflecting on the importance of this in-person time with the oncology community. we re excited about the updates shared this year and look forward to driving innovation forward for people impacted by cancer. | A pharma company dedicated to changing tomorrow by improving the health of people around the world. Tweets for U.S. audience. Guidelines: https://t.co/AJlgiDgp38 | Company / Organization | Pharma / Biotech |
not tagged | not tagged | astellas | not tagged | 1 | ['astellasus', 'astellas'] | 6/7/2022 13:51 | 1,530,000,000,000,000,000 | changing tomorrow! had the opportunity to visit the headquarters today and see this inspiring slogan. we are truly changing tomorrow by implementing the new data & advances from #asco22 & through the continuum of cancer care. | I treat & research GU cancers @UTSW Dallas. Columbia/Harvard Med/Duke alum; Mom & wife Tweets=my opinions ASCO: https://t.co/Whk29PATXe | Individual | HCP |
not tagged | not tagged | astellas | myeloid | 1 | ['leukemia', 'aml,(-streamline),(-seamless),(-kamloops),(-dreamlike)', 'aml,(-streamline),(-seamless),(-kamloops),(-latamleaders)', 'myeloid', 'astellasus', 'astellas'] | 6/7/2022 10:01 | 1,530,000,000,000,000,000 | during #asco22, we ve had the privilege of learning new insights and information from the #oncology community on hard-to-treat cancers like acute myeloid leukemia (#aml), where we strive to make a positive impact. | A pharma company dedicated to changing tomorrow by improving the health of people around the world. Tweets for U.S. audience. Guidelines: https://t.co/AJlgiDgp38 | Company / Organization | Pharma / Biotech |
enzamet,dasl-hicap | darolutamide,enzalutamide | astellas,orion corp,pfizer,bayer | gu | 1 | ['daslhicap', 'enzamet', 'in person'] | 6/4/2022 17:47 | 1,530,000,000,000,000,000 | great #itsc meetings with our collaborators about our #enzamet #enzarad & #daslhicap studies. great to see everyone in person & on #asco2022 | The Australian and New Zealand Urogenital and Prostate cancer trials group aims to develop, foster and promote prostate and other urogenital cancer research | Company / Organization | Healthcare |
enzamet,dasl-hicap | darolutamide,enzalutamide | astellas,orion corp,pfizer,bayer | gu | 1 | ['daslhicap', 'enzamet', 'in person'] | 6/4/2022 22:37 | 1,530,000,000,000,000,000 | what a pleasure to see many of the #daslhicap #enzamet & #enzarad team in person at #asco22 | Clinical trial program manager - oncology, @TrialsCentre @Sydney_Uni. PhD. She/her. | Individual | Research / Science |